Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 4/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764555 | 0.90 | TSHR (0.36) | LMNAMAPTMAPK1TSHRHPGD | |
| SCHEMBL25477462 | 0.86 | CES2 (0.35) | CES2TSHRTLR2 | |
| SCHEMBL22861699 | 0.85 | MEN1 (0.36) | CES2MEN1KMT2A | |
| SCHEMBL23696575 | 0.85 | MEN1 (0.36) | CES2MEN1KMT2A | |
| SCHEMBL25971783 | 0.85 | MEN1 (0.32) | TSHRMEN1KMT2ATLR2 | |
| SCHEMBL24765424 | 0.85 | MEN1 (0.38) | LMNAMAPTMAPK1TSHRHPGD | |
| SCHEMBL24672928 | 0.85 | MEN1 (0.38) | LMNAMAPTMAPK1TSHRHPGD | |
| SCHEMBL25476757 | 0.84 | MEN1 (0.37) | LMNAMAPTMAPK1TSHRMEN1 | |
| SCHEMBL25704437 | 0.82 | MEN1 (0.42) | CES2LMNAMAPTMAPK1TSHR | |
| SCHEMBL25122621 | 0.82 | MEN1 (0.37) | LMNAMAPTMAPK1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | CES2 885/4885LMNA 2448/4885MAPT 258/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CES2 1669/4885LMNA 1656/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.